Immune checkpoint inhibitor therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma.
Roger Y. Kim, MD, MSCE
Advertisement
Articles by Roger Y. Kim, MD, MSCE
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma
2
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
3
Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC
4
Hematologists Detail Practice-Shaping Data That Emerged at EHA 2026 (VIDEO)
5